DelveInsight’s, “Chronic Pain Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Chronic Pain pipeline landscape. It covers the Chronic Pain pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Chronic Pain Pipeline? Click here to explore the therapies and trials making headlines @ Chronic Pain Pipeline Outlook Report
Key Takeaways from the Chronic Pain Pipeline Report
- On 07 August 2025, noiVita Srls announced a study aims to identify a new treatment useful for managing chronic pain. For this purpose, patients suffering from chronic pain, attending the Alessandria Hospital Company, aged between 18 and 80, and using acetaminophen in the previous 3 months, would be enrolled.
- DelveInsight’s Chronic Pain Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Chronic Pain treatment.
- The leading Chronic Pain Companies such as Apurano Pharmaceuticals GmbH, Spine BioPharma, Inc, BioRestorative Therapies, ANANDA Scientific, Contineum Therapeutics, RaQualia Pharma Inc., Navega Therapeutics, Sustained Therapeutics Inc., Lohocla Research Corporation, Sangamo Therapeutics, Vertanical GmbH, Hanmi Pharmaceutical Company Limited and others.
- Promising Chronic Pain Therapies such as ST-01, Adezunap (AP707), JNS020QD, Fentanyl-TTS, Morphine, Duloxetine hydrochloride, Hydrocodone Bitartrate, Fentanyl Buccal Tablet and others.
Want to know which companies are leading innovation in Chronic Pain? Dive into the full pipeline insights @ Chronic Pain Clinical Trials Assessment
The Chronic Pain Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Chronic Pain Pipeline Report also highlights the unmet needs with respect to the Chronic Pain.
Chronic Pain Overview
Chronic pain is a widespread and debilitating condition that affects over a quarter of the U.S. population, making it one of the most common reasons for outpatient visits. Defined as pain lasting longer than three months, it can severely impair daily functioning and is frequently linked with mental health issues such as depression, anxiety, and an elevated risk of suicide. Managing chronic pain effectively requires a comprehensive approach that includes both pharmacologic and nonpharmacologic strategies. Despite this, inadequate treatment and an overdependence on opioids continue to pose significant challenges, driving up healthcare costs and fueling the ongoing opioid epidemic.
Chronic Pain Emerging Drugs Profile
- AP707: Apurano Pharmaceuticals GmbH
ADEZUNAP (AP707) is manufactured using the patented PuranoTec® manufacturing process so that the cannabinoids (primarily ∆-9-THC) are available as an aqueous nanodispersion. The dispersion is applied sublingually as a mouth spray and the cannabinoids are absorbed quickly and effectively via the oral mucosa. This is possible because the lipophilic, water-insoluble cannabinoids are enclosed in a carrier that is surrounded by a water-soluble shell, the smart coating. As so-called SmartLipids, they remain physically stable in an aqueous environment (no coalescence or agglomerate formation), which ensures passage through the aqueous mukin layer. On the other hand, due to the small particle size of
- BRTX 100: BioRestorative Therapies
BRTX‑100 is an innovative autologous mesenchymal stem cell–based therapy designed to treat chronic lumbar and cervical discogenic pain. The process begins with harvesting the patient’s own bone marrow, isolating and expanding stem cells under hypoxic conditions, and formulating a biologic secretome enriched with exosomes and growth factors. When administered via a single, minimally invasive intradiscal injection, BRTX‑100 aims to repair degenerative disc tissue and restore disc microenvironment homeostasis. Positioned as a non‑surgical alternative for patients who have not benefited from conservative treatments—such as opioids, injections, or physical therapy—BRTX‑100 offers potential for durable pain relief and functional improvement without the risks associated with surgery or systemic pharmacotherapy. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Pain.
- NANTHEIA: ANANDA Scientific
Nantheia™ A1002N5S is an oral cannabidiol (CBD) formulation developed using ANANDA Scientific’s patented Liquid Structure™ delivery technology, which enhances CBD bioavailability, solubility, and stability. Each softgel delivers 50 mg of pharmaceutical-grade CBD designed to provide effective dosing with consistent absorption. Targeting radiculopathic and other forms of chronic non-cancer pain, Nantheia aims to leverage CBD’s anti-inflammatory and analgesic properties to reduce opioid reliance and manage pain through a safer, non-addictive mechanism. Preclinical and early clinical data suggest improved pharmacokinetics and tolerability compared to conventional CBD formulations, offering potential as a well-tolerated therapeutic option in chronic pain management. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Pain.
- PIPE-791: Contineum Therapeutics
PIPE‑791 is a potent, brain-penetrant small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R), designed to address chronic pain associated with osteoarthritis and low back pain. By blocking LPA1R—a key mediator of neuroinflammation, neuronal hyperexcitability, and demyelination—PIPE‑791 is envisioned to modify the central mechanisms contributing to neuropathic pain. With demonstrated target engagement, anti-inflammatory activity, and remyelination potential in preclinical studies, PIPE‑791 offers potential as a non‑opioid therapeutic option that may reduce maladaptive pain signaling and provide durable relief while avoiding systemic opioid-related side effects. Currently, the drug is in Phase I stage of its development for the treatment of Chronic Pain.
If you’re tracking ongoing Chronic Pain Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Chronic Pain Treatment Drugs
Chronic Pain Companies
Apurano Pharmaceuticals GmbH, Spine BioPharma, Inc, BioRestorative Therapies, ANANDA Scientific, Contineum Therapeutics, RaQualia Pharma Inc., Navega Therapeutics, Sustained Therapeutics Inc., Lohocla Research Corporation, Sangamo Therapeutics, Vertanical GmbH, Hanmi Pharmaceutical Company Limited and others.
The Chronic Pain Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Pain with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Pain Treatment.
- Chronic Pain Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Chronic Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Pain market.
Chronic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Chronic Pain Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
From emerging drug candidates to competitive intelligence, the Chronic Pain Pipeline Report covers it all – check it out now @ Chronic Pain Market Drivers and Barriers, and Future Perspectives
Scope of the Chronic Pain Pipeline Report
- Coverage- Global
- Chronic Pain Companies- . Apurano Pharmaceuticals GmbH, Spine BioPharma, Inc, BioRestorative Therapies, ANANDA Scientific, Contineum Therapeutics, RaQualia Pharma Inc., Navega Therapeutics, Sustained Therapeutics Inc., Lohocla Research Corporation, Sangamo Therapeutics, Vertanical GmbH, Hanmi Pharmaceutical Company Limited and others.
- Chronic Pain Therapies such as ST-01, Adezunap (AP707), JNS020QD, Fentanyl-TTS, Morphine, Duloxetine hydrochloride, Hydrocodone Bitartrate, Fentanyl Buccal Tablet and others.
- Chronic Pain Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Chronic Pain Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research – discover what’s next for the Chronic Pain Treatment landscape in this detailed analysis @ Chronic Pain Emerging Drugs and Major Players
Table of Content
- Introduction
- Executive Summary
- Chronic Pain: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chronic Pain– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- AP707: Apurano Pharmaceuticals GmbH
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BRTX 100: BioRestorative Therapies
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- PIPE-791: Contineum Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Pain Key Companies
- Chronic Pain Key Products
- Chronic Pain- Unmet Needs
- Chronic Pain- Market Drivers and Barriers
- Chronic Pain- Future Perspectives and Conclusion
- Chronic Pain Analyst Views
- Chronic Pain Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-pain-pipeline-insight